Business Context and Reporting Period
Maze Therapeutics, Inc. (MAZE) filed a Form 8-K on February 2, 2026, reporting the entry into a material definitive agreement on February 4, 2026. The filing details a new senior secured term loan facility with Hercules Capital, Inc. and the simultaneous termination of a prior loan agreement with Banc of California.
Key Financial Metrics and Debt Structure
- Total Facility Size: Up to $200.0 million in aggregate principal amount.
- Initial Funding (Tranche 1A): $40.0 million funded on the Closing Date.
- Net Proceeds: Approximately $38.4 million after deducting estimated debt issuance costs and fees.
- Future Availability: Up to $160.0 million in additional tranches available within 60 months, subject to performance milestones and lender approval.
- Maturity Date: February 1, 2031.
- Interest Rate: Prime rate plus a floor ranging from 7.95% to 9.25% depending on the tranche. Interest-only payments are required for 48 to 60 months.
- Exit Fees: 3.95% (if repaid within 24 months), 5.75% (24-48 months), or 6.45% (after 48 months) of the principal amount repaid.
- Prepayment Premiums: Range from 3.00% (within 12 months) to 0.00% (after 36 months).
Material Changes Versus Prior Period
The Company terminated its Loan and Security Agreement with Banc of California, dated June 27, 2022, effective February 2, 2026. Consequently, Banc of California's security interest in the Company's assets was released. This was replaced by a first lien perfected security interest on substantially all existing and after-acquired assets in favor of the lenders under the new Hercules Loan Agreement.
Guidance, Covenants, and Risks
- Liquidity Covenants: Unless market capitalization exceeds $450 million (with loan balance under $85 million) or $750 million, the Company must maintain unrestricted cash and cash equivalents of at least 50% of the outstanding loan amount. This requirement decreases to 40% and 35% upon satisfying certain milestones.
- Restrictive Covenants: The agreement limits the Company's ability to incur new indebtedness, create liens, engage in mergers or acquisitions, make investments, or make distributions without exceptions.
- Events of Default: Include non-payment, covenant violations, bankruptcy, material judgments, and change of control. Default triggers an automatic interest rate increase of 4.00% per annum and potential acceleration of all outstanding principal and interest.
- Management Commentary: The filing does not provide specific management commentary on future operational guidance beyond the terms of the financing agreement.
Investor Verification Checklist
- Verify the Company's current market capitalization to determine applicable liquidity covenant thresholds.
- Confirm the specific performance and financing milestones required to access the remaining $160.0 million in tranches.
- Review the full text of the Hercules Loan Agreement (to be filed as an exhibit to the Q1 2026 Form 10-Q) for detailed covenant definitions and exceptions.
- Assess the impact of the interest rate floors (7.95% to 9.25%) on future cash flow projections.
- Monitor the Company's unrestricted cash balance to ensure compliance with the 50% (or reduced) cash maintenance covenant.